PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment strategies.

A meta-analysis of 102 studies and 3,943 participants found no significant cognitive differences across menstrual phases.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements.

Interval breast cancer rates have remained consistent over 30 years despite age-based screening, highlighting the need for ...

Triple negative breast cancer accounts for 15% of cases but causes a disproportionate number of deaths. Learn about symptoms ...

Maternal stress is a major risk factor for preterm birth (PTB), with recent mouse studies highlighting the role of FKBP51 in ...

Too few people get diagnosed and treated for postpartum depression. But a blood test could change that Postpartum depression ...

Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...